- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03042013
A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study
An Open-label, Multicenter, Rollover Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a multicenter, rollover study for subjects with non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) activating mutation who are currently participating in studies evaluating ASP8273.
Subjects should sign the informed consent at cycle 1 day 1 visit. The assessments from the last treatment visit from the parent study can be utilized for the cycle 1 day 1 visit. Either local or central laboratories may be utilized for the cycle 1 day 1 visit if assessments are used from the last treatment visit of the parent study. The subject will then receive ASP8273 study drug for the rollover study and return all ASP8273 study drug from the parent study. Subjects will continue on to subsequent 28-day cycles until 1 of the discontinuation criteria are met. Upon enrollment, subjects with fewer than 6 cycles of study drug dosing in the parent study will return to the clinic on day 1 of each cycle up to cycle 5. After cycle 5, these subjects can switch to day 1 of every other odd cycle for clinic visits. Subjects with 6 or more cycles of study drug dosing upon enrollment into the rollover study will return to the clinic on day 1 of every other odd cycle (e.g., cycles 3, 5, etc.). Imaging methods and frequency will be performed per standard of care.
An end of treatment study visit will be conducted 30 days after the last dose of study medication.
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject must be participating in an Astellas-sponsored ASP8273 study which has completed, at a minimum, the primary analysis or have completed the individual study evaluation period requirements. Subject must not have met any discontinuation criteria in the parent study.
- Subject must be receiving a stable dose of ASP8273 for 14 days minimum and is able to enroll into this rollover study without treatment interruption of study drug, or with no more than 21 consecutive days of treatment interruption in study drug within the parent study.
- Subject should be deriving clinical benefit without any persistent intolerable toxicity from continued treatment of ASP8273.
- Subject agrees not to participate in another interventional study while on treatment.
Exclusion Criteria:
- Subject who developed persistent intolerable toxicity to ASP8273 treatment in the parent study.
- Subject who received any other systemic anticancer treatment after parent study entry (radiation to local areas such as bone or brain if received in the parent ASP8273 study is permitted).
Subject who requires the following medications will be excluded:
- Chemotherapy, radiotherapy, immunotherapy or other medications intended for antitumor activity
- Investigational products or therapy other than ASP8273
- Strong inhibitors or inducers of CYP3A4
- Permeability-glycoprotein (P-gp) substrates with a narrow therapeutic index
- Subject has any condition which may require treatment during the study and may make the subject unsuitable for study participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ASP8273
Subjects will receive a once or twice daily oral dose of ASP8273 (3 dose strengths)
|
Oral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events (safety and tolerability)
Time Frame: Up to a maximum of 1 month (per cycle)
|
An Adverse Event (AE) is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product
|
Up to a maximum of 1 month (per cycle)
|
Number of participants with laboratory value abnormalities and/or adverse events related to treatment
Time Frame: Up to a maximum of 1 month (per cycle)
|
Number of participants with potentially clinically significant laboratory values
|
Up to a maximum of 1 month (per cycle)
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 8273-CL-0201
- 2016-003183-39 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Subjects With NSCLC With an EGFR Activating Mutation
-
Tianjin Medical University Cancer Institute and...Not yet recruitingNSCLC | EGFR Activating Mutation | Anlotinib | TP53 | Aumolertinib
-
Coloplast A/SCompletedSubjects With an IleostomyDenmark
-
Chinese University of Hong KongPamela Youde Nethersole Eastern HospitalCompleted
-
AstraZenecaCompletedCaucasian Patients With EGFR Mutation Positive Advanced NSCLCBulgaria, Italy, Poland, Spain, Turkey, United Kingdom, Romania, Norway, Hungary, Portugal, Greece, Switzerland, France
-
Centre Francois BaclesseHoffmann-La Roche; Groupe Francais De Pneumo-CancerologieTerminatedNSCLC Patients With EGFR Activating MutationFrance
-
Henan Cancer HospitalUnknownAdvanced NSCLC With EGFR MutationChina
-
Medtronic - MITGCompletedSubjects With an Existing Intra-arterial LineUnited States
-
The University of Hong KongUnknownNSCLC Stage IV | EGFR Activating Mutation | NSCLC Stage IIIBHong Kong
-
Peking Union Medical CollegeRecruitingNSCLC Stage IV | EGFR Activating Mutation | NSCLC Stage IIIB | NSCLC, RecurrentChina
-
Rain Oncology IncTerminatedNSCLC Stage IIIB | NSCLC, Recurrent | NRG1 Fusion | EGFR Exon 20 Insertion Mutation | NSCLC, Stage IIIC | NSCLC, Stage IV | HER2-activating Mutation | ERBB FusionUnited States, Canada, Hong Kong
Clinical Trials on ASP8273
-
Astellas Pharma IncTerminatedEGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating MutationsJapan
-
Astellas Pharma IncTerminatedNon-small Cell Lung CancerJapan, Korea, Republic of, Taiwan
-
Astellas Pharma Global Development, Inc.TerminatedNon-small Cell Lung Cancer (NSCLC) | Epidermal Growth Factor Receptor (EGFR) MutationsUnited States
-
Astellas Pharma Global Development, Inc.WithdrawnSolid Tumors | Epidermal Growth Factor Receptor (EGFR) Mutations
-
Astellas Pharma Global Development, Inc.TerminatedNon-small Cell Lung Cancer (NSCLC)United States, Australia, Belgium, Canada, Chile, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Portugal, Romania, Russian Federation, Singapore, Spain, Taiwan, Thailand, Ukraine, United Kingdom
-
Astellas Pharma Global Development, Inc.CompletedNon-Small-Cell Lung Cancer (NSCLC) | Epidermal Growth Factor Receptor MutationsUnited States